4th Quarter - Report

CAPITOL HILL CONSULTING GROUP for ENDO PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues relating to incentives for life sciences research. H.R. 160 - Protect Medical Innovation Act of 2015. Tax treatment of inverted companies. Tax issues in mergers and acquisitions of US firms.

LobbyistCovered position, as disclosed
DAVID JORY —
WILLIAM STEVE SOUTHERLAND William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
BRIAN SUTTER New Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14 Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13 Leg Dir. Rep. Dave Camp, May'08-Jan'11 Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02-

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 160 (114th)

Pharmacy PHA

Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825

LobbyistCovered position, as disclosed
DAVID JORY —
WILLIAM STEVE SOUTHERLAND William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
BRIAN SUTTER New Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14 Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13 Leg Dir. Rep. Dave Camp, May'08-Jan'11 Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2825 (114th)

Health Issues HCR

Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market HR 5046/S 524 - Opioid abuse legislation H.R.4641 - To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.

LobbyistCovered position, as disclosed
DAVID JORY —
WILLIAM STEVE SOUTHERLAND William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
BRIAN SUTTER New Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14 Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13 Leg Dir. Rep. Dave Camp, May'08-Jan'11 Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4641 (114th), H.R. 471 (114th), S. 483 (114th), S. 2948 (114th), H.R. 5748 (114th), S. 524 (114th), H.R. 5046 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.